Current Status and Clinical Application Value of Thailand Embryo Genetic Database Technology
AI Summary
Reproductive Specialist · Clinical Decision Perspective
1. Three Core Variables in Clinical Decision-Making
In the practical application of embryo genetic database technology, the decision-making pathway typically revolves around three core variables: the number of available embryos, the clarity of the genetic etiology, and the history of previous transfers. When the number of embryos is sufficient (usually ≥5 blastocysts) and there is a clear genetic indication, the clinical value of this technology is most evident. If the number of embryos is low (≤3), or the genetic etiology has not been verified through a proband, the risks of biopsy and potential benefits need to be carefully weighed.
Taking referral cases I have encountered as an example, some patients come for consultation with the expectation that "Thailand's PGT technology is more advanced." However, after evaluation, it turns out that what they truly need is not more complex genetic testing but basic chromosomal screening combined with strict laboratory quality control. This illustrates that technology selection should be guided by clinical indications, not by geographical location or marketing labels.
2. Thailand Embryo Genetic Database Technology: Direct Answer
Thailand embryo genetic database technology essentially refers to a technical system that uses next-generation sequencing (NGS) and single nucleotide polymorphism arrays (SNP Array) as core platforms to perform whole-genome or targeted region sequencing on trophectoderm cells. This is combined with comparative analysis against a local population genetic background database to assess embryo chromosomal copy number variations, structural rearrangements, and carrier status for pathogenic genes.
The clinical outputs of this technology include: preimplantation genetic testing for aneuploidy (PGT-A), preimplantation genetic testing for monogenic disorders (PGT-M), and preimplantation genetic testing for chromosomal structural rearrangements (PGT-SR). Some reproductive centers in Thailand have accumulated a certain scale of local embryo genetic data, which can be used to optimize embryo grading and prioritize transfer order.
3. Technical Principle: Why an Embryo Genetic Database is Needed
The core difficulty of embryo genetic testing lies not in the sequencing itself, but in the accuracy of data interpretation. An embryo's genomic data needs to be compared against a reference database to determine the presence of pathogenic variants. The value of the Thailand embryo genetic database lies in:
- Localized Background Frequency Correction: SNP allele frequencies vary among different populations. Using a local database can reduce the misclassification rate of "variants of uncertain significance."
- Structural Rearrangement Breakpoint Localization: For carriers of balanced chromosomal translocations, breakpoint hotspot information in the database can improve detection accuracy.
- Mosaicism Interpretation Reference: The threshold for the embryonic mosaicism ratio requires support from the laboratory's own validation data.
Some centers in Thailand have invested significantly in database construction, but overall, the scale of their databases still lags behind large multi-center databases in Europe and the United States. This means that for certain rare variants or de novo mutations, comprehensive judgment still requires combining family verification and public databases (such as ClinVar, gnomAD).
4. Comparison of Technical Differences Among Countries
| Dimension | Thailand | United States | China (Mainland) | Europe (Representative Countries) |
|---|---|---|---|---|
| Main Platform | NGS (Illumina) + SNP Array | NGS + aCGH + SNP Array | Primarily NGS, some centers use MALBAC | NGS + aCGH |
| Database Localization | Medium-scale local database, some centers have accumulated data | Large-scale multi-center database | Relies on public databases + some centers have self-built databases | Multi-center joint database |
| Clinical Indication Control | Relatively flexible, broad range of indications | Strictly follows ACMG guidelines | Refer to consensus, slight variations among centers | Follows ESHRE guidelines |
| Mosaicism Reporting Rate | Reporting rate about 3%–8%, thresholds vary | Reporting rate about 5%–10%, unified guidelines exist | Reporting rate about 4%–8%, thresholds gradually standardizing | Reporting rate about 5%–9%, guidelines available |
| Genetic Counseling Support | Some centers have dedicated genetic counselors | Standard genetic counselors | Large centers have genetic counseling, weak at grassroots level | Standard genetic counselors |
As shown in the table, Thailand keeps pace internationally in terms of technical platforms, but there are certain differences in database scale and genetic counseling support. This directly affects the depth of result interpretation and the precision of clinical decision-making.
5. A Clinician's Perspective on Thailand Embryo Genetic Database Technology
In actual consultations, I often encounter two types of situations: one is patients who bring PGT reports from Thai laboratories abroad and want domestic centers to make transfer decisions; the other is those planning to go to Thailand for PGT treatment and seeking a preliminary assessment of technical feasibility.
For the first type, key review points include: the type of testing platform, data quality control parameters (such as sequencing depth, coverage uniformity), mosaicism interpretation criteria, and genetic counseling records. Some Thai laboratory report formats differ from international standards, for example, not indicating sequencing depth or not providing raw data QC metrics, which introduces some uncertainty into clinical decision-making.
For the second type, I focus on assessing whether the patient truly needs PGT and whether the Thai laboratory's technology can meet their specific needs. For example, for known familial monogenic diseases, it is necessary to confirm whether the laboratory has the capability for targeted testing of that gene and whether it possesses local validation data for that specific site.
6. The Most Easily Overlooked Detail: Database ≠ Diagnostic Gold Standard
A common misconception is equating embryo genetic database technology with a "diagnostic" technology. In reality, PGT is a screening technology; its results are probabilistic, not diagnostic. The role of the database is to improve the reference accuracy for interpretation, but it cannot eliminate the following inherent limitations:
- Mosaicism Misjudgment: Low-level mosaicism (<20%) may be reported as euploid, while high-level mosaicism (>80%) may be reported as aneuploid.
- Variants of Uncertain Significance: Databases cannot cover all rare variants; some VUS still require family co-segregation analysis.
- Mitochondrial Diseases: Nuclear gene databases cannot detect mitochondrial DNA mutations; additional configuration is required if needed.
- Methylation Abnormalities: Existing databases do not contain methylation information, limiting detection capability for imprinting disorders.
Ignoring these details can lead to over-interpretation of test results, thereby affecting transfer decisions.
7. Common Pitfalls: Indication Overgeneralization and Result Misinterpretation
In the actual medical process, the following three pitfalls are relatively common:
- Indication Overgeneralization: Some institutions recommend PGT-A to all IVF patients, including young patients without clear indications. In fact, for women aged <35 years with no history of miscarriage or genetic disease, PGT-A does not improve cumulative live birth rates and may instead reduce the number of viable embryos due to biopsy damage.
- Result Misinterpretation – Equating "Low-level Mosaicism" with "Non-transferable": Some laboratories report embryos with a mosaicism ratio of 10%–20% as "abnormal." In reality, such embryos can still be considered for transfer after thorough genetic counseling, and the rate of chromosomally normal live births is relatively high. A one-size-fits-all interpretation standard wastes usable embryos.
- Ignoring Maternal Contamination: Maternal cell contamination in embryo biopsy samples can lead to result bias, but not all laboratories routinely perform contamination detection (e.g., using STR loci or SNP fingerprinting).
8. Actual Process: From Ovarian Stimulation to Genetic Report
The complete process for embryo genetic testing in Thailand typically includes the following steps:
- Ovarian Stimulation and Egg Retrieval: Conventional controlled ovarian stimulation, followed by ICSI fertilization after egg retrieval.
- Blastocyst Culture: Culture until Day 5–6, forming blastocysts before biopsy. Usually, at least 3–5 blastocysts are required for testing.
- Trophectoderm Biopsy: Under a microscope, 3–5 cells are aspirated from the trophectoderm of the blastocyst and sent to the genetic laboratory.
- Whole Genome Amplification (WGA): Whole genome amplification is performed on the微量 cells to obtain sufficient DNA for sequencing.
- Library Construction and Sequencing: Sequencing is performed using NGS or SNP chip platforms, with a turnaround time of approximately 4–7 days.
- Data Comparison and Interpretation: Comparison against a reference database to determine chromosomal copy number status and carrier status for pathogenic genes.
- Report Issuance and Genetic Counseling: The final report is usually available 10–14 days after egg retrieval, followed by genetic counseling and transfer decision-making.
9. Timeline and Factors to Consider
| Stage | Approximate Time | Key Considerations |
|---|---|---|
| Ovarian Stimulation Cycle | 10–14 days | Genetic counseling and informed consent must be completed in advance |
| Blastocyst Culture + Biopsy | 5–6 days | Laboratory must have experience in blastocyst culture; biopsy procedures must be standardized |
| WGA + Sequencing | 4–7 days | Quality control metrics include amplification uniformity and allele dropout rate |
| Data Interpretation + Report | 2–4 days | Require interpretation basis, database version, and QC parameters |
| Genetic Counseling + Transfer | 1–2 days | Must integrate embryo morphological grading and maternal factors for comprehensive decision-making |
Overall, from egg retrieval to obtaining a transferable genetic test result, it takes approximately 14–20 days. If frozen embryo transfer is performed, the timeline is more flexible.
10. Frequently Asked Questions
Q1: Can Thailand embryo genetic database technology screen for all genetic diseases?
No. Current technology mainly covers chromosomal aneuploidies, large fragment structural rearrangements, and monogenic diseases with known pathogenic sites. Detection capability is limited for polygenic diseases, rare de novo mutations, and mitochondrial diseases.
Q2: Does a normal test result mean the embryo is definitely healthy?
No. A normal PGT result only indicates that no clear pathogenic abnormality was found within the detection range, but it cannot rule out mosaicism, methylation abnormalities, or variants outside the detection range. Routine prenatal screening and diagnosis are still required after a live birth.
Q3: Is Thailand's PGT technology more advanced than that in China?
The technical platforms themselves are not significantly different. The main differences lie in the degree of database localization, laboratory quality control systems, and the completeness of genetic counseling. The choice should be based on the specific quality control indicators of the laboratory, rather than simply comparing countries.
Q4: Which groups are not recommended for embryo genetic testing?
Individuals with very few embryos (≤2), no clear genetic indication, or financial constraints that cannot afford repeated testing costs are not recommended to undergo PGT blindly. Additionally, for mitochondrial diseases or imprinting disorders, the value of current PGT technology is limited.
Q5: What is the approximate cost range for embryo genetic testing in Thailand?
The cost varies depending on the testing scope (PGT-A / PGT-M / PGT-SR) and the number of embryos. Typically, the testing cost per embryo is in the range of 3000–6000 RMB (estimated at current exchange rates), plus biopsy fees and genetic counseling fees. The total cost is approximately 15,000–40,000 RMB. Consult the target laboratory for specific details.
